The mission of the OSUCCC Biomedical Informatics Shared Resource (BISR) is to advance cancer research throughout the OSUCCC by providing end-users with advanced biomedical informatics services and expertise. End-users include OSUCCC leadership, investigators, research staff, trainees, and other shared resources (SRs) and scientific programs (SPs). In the last CCSG award cycle, the BISR was a developing shared resource and in this cycle will serve as a full shared resource. The BISR accomplishes its mission through a number of mechanisms, including the following specific services: 1) customization, deployment, and management of caBIG technologies and platforms in support of clinical and bio-molecular data management and integration requirements;2) the execution of complex data analyses that require bioinformatics and computational-biology expertise;and 3) biomedical informatics consulting, project planning, and training. The BISR is organized into two complementary arms, focusing on Computational Biology Services (CBS) and Data Management Services (DMS). The CBS arm of the BISR provides end-users with services, including the planning and execution of SP- or SR-specific data management applications and analytical workflows, with an emphasis on the utilization of high throughput biological data, such as that generated by OSUCCC instrumentation SRs. The DMS arm of the BISR provides technical services and expertise in support of the adoption, customization, and use of caBIG technologies and platforms to facilitate SP- and SR-specific data management requirements, with an emphasis on the provision of data-analytic pipelines that enable end-users to identify, integrate, exchange, and analyze heterogeneous and distributed data sets/sources. In addition, the DMS arm facilitates OSUCCC end-user access to enterprise-wide clinical informatics tools and data sources, such as the Medical Center's Information Warehouse (a comprehensive enterprise-wide data warehouse), as well as the data management tools and resources being developed by the CTSA-funded OSU Center for Clinical and Translational Science (CCTS). The BISR serves as a catalyst throughout the OSUCCC to integrate and rapidly translate discoveries from the lab to cancer treatment and prevention.
The OSUCCC Biomedical Informatics Shared Resource (BISR) provides a suite of services, technologies, and expertise that support the timely and efficient conduct of basic, clinical, and translational research projects. The BISR provides OSUCCC members with access to: 1) informatics consultation services in order to assist such end-users to identify and engage informatics methods and tools throughout their active or planned activities;2) data management, exchange, and analysis tools and platform;and 3) complex data analysis methods requiring bioinformatics and computational-biology expertise.
|Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819|
|Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294|
|Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859|
|Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954|
|Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471|
|Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427|
|Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322|
|Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874|
|Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814|
|Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :|
Showing the most recent 10 out of 2211 publications